Current Research Studies

AAML18P1, Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)

AAML18P1

What is the goal of the study?

The goal of this study is to answer the following question: What is the two-year treatment-free remission rate of children and young adults with chronic myeloid leukemia - chronic phase (CML-CP) after taking tyrosine kinase inhibitors (TKI) for at least three years? Researchers also hope to estimate the remission rate after one year in patients who have to restart TKI therapy.

Who can participate in the study?

This study may be a good for for children and young adults who: -Were diagnosed with chronic myeloid leukemia - chronic phase (CML-CP) at less than 18 years of age and are currently less than 25 years of age -Have received any TKI therapy for a minimum of three consecutive years at time of enrollment and are willing to discontinue TKI therapy You can read more about the eligibility criteria for this study on clinicaltrials.gov. Researchers use many other factors to decide whether a patient can take part in a study (inclusion criteria) or cannot take part (exclusion criteria). The study team at Seattle Children’s can explain what these factors mean for you or your child.

Study Team: